Allos Therapeutics Inc - Current report filing (8-K)
19 May 2008 - 8:45PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
May 19, 2008
ALLOS THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
Delaware
|
|
000-29815
|
|
54-1655029
|
(State or other jurisdiction
|
|
(Commission
|
|
(IRS Employer
|
of incorporation)
|
|
File Number)
|
|
Identification No.)
|
11080 CirclePoint Road, Suite 200
|
|
|
Westminster, Colorado
|
|
80020
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code:
(303) 426-6262
Not applicable
(Former name or former address, if changed since last report.)
Check the appropriate box
below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions (see
General Instruction A.2. below):
o
Written communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
Section 7 Regulation FD
Item 7.01. Regulation FD Disclosure.
On
May 19, 2008,
Allos
Therapeutics, Inc., a Delaware corporation (the Company), issued a press release announcing that the
Company is initiating a public offering of 9,000,000 shares of its common
stock, par value $0.001 per share (not including 1,350,000 shares to be offered
to the underwriters pursuant to an overallotment option). A copy of the press release is filed as Exhibit 99.1
to this report and is incorporated herein by reference.
In
accordance with General Instruction B.2 of Form 8-K, the information
presented under this Item 7.01 and attached as Exhibit 99.1 shall not
be deemed filed for purposes of Section 18 of the Securities Exchange
Act of 1934, as amended, nor shall it be deemed incorporated by reference in
any filing under the Securities Act of 1933, as amended, except as expressly
set forth by specific reference in such a filing.
Item 9.01 Financial Statements and
Exhibits.
(d) Exhibits
|
99.1
|
Press
Release, dated May 19, 2008, entitled Allos Therapeutics Announces Public Offering of 9,000,000 Shares of
Common Stock.
|
2
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this
report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: May 19, 2008
|
|
ALLOS
THERAPEUTICS, INC.
|
|
|
|
|
|
|
|
By:
|
/s/
Marc H. Graboyes
|
|
|
Marc
H. Graboyes
|
|
Its:
|
Senior
Vice President, General Counsel and Secretary
|
3
EXHIBIT
INDEX
Exhibit No.
|
|
Description
|
|
|
|
99.1
|
|
Press
Release, dated May 19, 2008, entitled Allos Therapeutics Announces Public Offering of 9,000,000 Shares of
Common Stock.
|
4
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Historical Stock Chart
From Jul 2023 to Jul 2024